# First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors

> **NCT02937116** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 233 (actual)

## Conditions studied

- Cancer, Solid Tumor

## Interventions

- **DRUG:** IBI308
- **DRUG:** IBI308\Cisplatinum\Pemetrexed
- **DRUG:** IBI308\cisplatin\gemcitabine
- **DRUG:** IBI308\oxaliplatin\capecitabine
- **DRUG:** IBI308\etoposide\cisplatin
- **DRUG:** IBI308\irinotecan\5-FU

## Key facts

- **NCT ID:** NCT02937116
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-19
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2022-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02937116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02937116, "First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02937116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*